The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.
 
Emanuela Palmerini
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Deciphera; EUSA Pharma; EUSA Pharma; Lilly
Research Funding - Daiichi Sankyo; PharmaMar (Inst)
Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo; Lilly; Takeda
 
Antonio Lopez-Pousa
No Relationships to Disclose
 
Giovanni Grignani
Honoraria - Bayer; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Pfizer; PharmaMar
Consulting or Advisory Role - Bayer; Eisai; PharmaMar
Research Funding - PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar; tesaro
 
Andres Redondo
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar; Roche
Research Funding - Eisai (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Nadia Hindi
Honoraria - Lilly; PharmaMar
Research Funding - Amgen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Silvia Stacchiotti
Honoraria - Lilly; PharmaMar; Takeda
Consulting or Advisory Role - Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; Immune Design; Lilly; MaxiVax; PharmaMar
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines; Daiichi Sankyo (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Ana Sebio
No Relationships to Disclose
 
Jose A. Lopez-Martin
Stock and Other Ownership Interests - PharmaMar
Consulting or Advisory Role - Amgen; Amgen; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Caris Life Sciences; Celgene; GlaxoSmithKline; Lilly; MSD Oncology; Novartis; Pfizer; PharmaMar; Pierre Fabre; Roche; Roche Molecular Diagnostics (Inst)
Patents, Royalties, Other Intellectual Property - PharmaMar
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology; MSD Oncology; Roche; Roche
 
Claudia Maria Valverde Morales
Consulting or Advisory Role - Bayer; Eisai; Lilly; Novartis; Pfizer; PharmaMar
Research Funding - Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Novartis; Pfizer; PharmaMar
 
Javier Martinez-Trufero
Consulting or Advisory Role - PharmaMar
Research Funding - Blueprint Medicines (Inst); Lilly (Inst); PharmaMar (Inst)
Expert Testimony - PharmaMar
Travel, Accommodations, Expenses - Amgen; Merck; PharmaMar; PharmaMar
 
Antonio Gutierrez
No Relationships to Disclose
 
Enrique de Alava
No Relationships to Disclose
 
Lorenzo D'Ambrosio
Consulting or Advisory Role - PSI
Research Funding - AstraZeneca (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - Celgene; Lilly; PharmaMar
 
Paola Collini
No Relationships to Disclose
 
Piero Picci
No Relationships to Disclose
 
Paolo Giovanni Casali
Consulting or Advisory Role - Bayer; Deciphera
Speakers' Bureau - Pfizer
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
 
Javier Martin Broto
Honoraria - Bayer; Eisai; Lilly; PharmaMar
Consulting or Advisory Role - Amgen; Bayer; GlaxoSmithKline; Novartis; PharmaMar
Speakers' Bureau - PharmaMar
Research Funding - Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); PharmaMar
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar